84. サルコイドーシス Disease details / Clinical trials / Drug dev / DR info

1% lignocaine
   Postgraduate Institute of Medical Education and Research
      2014   Phase 2/Phase 3   NCT01955824   India
13nh3 PET/CT scan
   Mayo Clinic
      2018   Phase 4   NCT03549598   United States
18F-FDG
   Tokushima University Hospital
      2010   -   JPRN-UMIN000004267   Japan
   University of Edinburgh
      2017   -   NCT03705884   United Kingdom
18F-FDG-PET/MRI
   St. Olavs Hospital
      2018   -   NCT03561025   Norway
18F-fluorodeoxyglucose
   Turku PET Centre
      2016   Phase 2   EUCTR2015-001815-11-FI   Finland
18F-fluorodeoxyglucose (18F-FDG) PET/CT
   British Columbia Cancer Agency
      2012   -   NCT01764191   Canada
18F-fspg
   Stanford University
      2017   Phase 2   NCT03103490   United States
18F-GE180-PET/MRI
   St. Olavs Hospital
      2018   -   NCT03561025   Norway
18FDG PET/CT scan
   Mayo Clinic
      2018   Phase 4   NCT03549598   United States
2% lignocaine
   Postgraduate Institute of Medical Education and Research
      2014   Phase 2/Phase 3   NCT01955824   India
64CU-dotatate PET/CT scan
   Rigshospitalet, Denmark
      2023   -   NCT06131112   Denmark
68GA-DOTA-TOC PET/CT
   Vastra Gotaland Region
      2020   -   NCT04206163   Sweden
68GA-dotanoc
   Turku PET Centre
      2016   Phase 2   EUCTR2015-001815-11-FI   Finland
68GA-dotatate PET/CT
   Mayo Clinic
      2018   Phase 4   NCT03549598   United States
68ganota-ANTI-MMR-VHH2
   Universitair Ziekenhuis Brussel
      2021   Phase 2   NCT04758650   Belgium
99M technetium infliximab
   Sint Antonius Hospital
      2011   -   EUCTR2011-003630-13-NL   Netherlands
99MTC-infliximab
   Sint Antonius Hospital
      2011   -   EUCTR2011-003630-13-NL   Netherlands
Abatacept
   University of Chicago
      2008   Phase 2   NCT00739960   United States
Ablation
   Western Sydney Local Health District
      2020   -   NCT05524077   Australia
Abpc
   Respiratory medicine, Juntendo university.
      2012   -   JPRN-UMIN000008813   Japan
Abrocitinib 200 MG
   Yale University
      2023   Phase 2   NCT05696795   United States
ACT-293987 / JNJ-67896049
   ACTELION PHARMACEUTICALS LTD
      2019   Phase 2;Phase 3   EUCTR2018-004887-74-IT   Belgium;Brazil;Canada;Czechia;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
   Actelion Pharmaceuticals Ltd
      2020   Phase 2   EUCTR2018-004887-74-DE   Belgium;Brazil;Canada;Czechia;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
      2019   Phase 2;Phase 3   EUCTR2018-004887-74-PL   Argentina;Belgium;Brazil;Canada;China;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004887-74-NL   Belgium;Brazil;Canada;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
      2019   Phase 2;Phase 3   EUCTR2018-004887-74-HU   Argentina;Belgium;Brazil;Canada;China;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004887-74-GB   Belgium;Brazil;Canada;Czechia;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
      2019   Phase 2;Phase 3   EUCTR2018-004887-74-ES   Argentina;Belgium;Brazil;Canada;China;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
Acthar GEL
   Albany Medical College
      2015   Phase 2/Phase 3   NCT02155803   United States
   Mallinckrodt
      2018   Phase 4   NCT03320070   United States
   University of California, San Francisco
      2022   Phase 4   NCT02523092   United States
   University of Cincinnati
      2014   Phase 4   NCT02188017   United States
Acthar GEL 40 units twice weekly
   Albany Medical College
      2015   Phase 2/Phase 3   NCT02348905   United States
ACZ885
   Novartis Pharma Services AG
      2016   Phase 2   EUCTR2016-001255-49-NL   Germany;Netherlands;United States
      2016   Phase 2   EUCTR2016-001255-49-DE   Germany;Netherlands;United States
      2015   -   EUCTR2013-005333-21-NL   Netherlands;United States
   Novartis Pharmaceuticals
      2016   Phase 2   NCT02888080   Germany;Netherlands;United States
Adalimumab
   Pariser, Robert J., M.D.
      2006   Phase 2   NCT00274352   United States
   University of Chicago
      2006   Phase 2   NCT00311246   United States
   Wake Forest University
      2007   Phase 2   NCT00690911   United States
Adrenocorticotropic hormone
   Albany Medical College
      2015   Phase 2/Phase 3   NCT02155803   United States
ALL subjects will receive maraviroc 300MG orally twice A DAY FOR 6 weeks
   Kevin F. Gibson
      2014   -   NCT02134717   United States
Allogeneic stem cell transplantation
   Northwestern University
      2003   Phase 1/Phase 2   NCT00282438   United States
Ambrisentan
   Medical University of South Carolina
      2008   Phase 2/Phase 3   NCT00851929   United States
Ampc
   Respiratory medicine, Juntendo university.
      2012   -   JPRN-UMIN000008813   Japan
Anakinra
   Virginia Commonwealth University
      2020   Phase 2   NCT04017936   United States
Analysis OF gamma globulin
   Rennes University Hospital
      2017   -   NCT03259282   France
Antibiotic regimen
   Vanderbilt University
      2010   Phase 1/Phase 2   NCT01074554   United States
Antituberculous therapy along with steroids
   Postgraduate Institute of Medical Education and Research
      2009   -   NCT01245036   India
ARA 290
   Araim Pharmaceuticals
      2013   -   EUCTR2013-003016-45-NL   Netherlands;United States
   Araim Pharmaceuticals, Inc.
      2014   Phase 2   NCT02039687   Netherlands;United States
Armodafinil
   University of Cincinnati
      2007   Phase 2/Phase 3   NCT00555347   United States
Atorvastatin
   National Heart, Lung, and Blood Institute (NHLBI)
      2006   Phase 2   NCT00279708   United States
ATYR1923
   ATYR PHARMA, INC.
      2023   Phase 3   EUCTR2022-001012-26-IT   France;Germany;Italy;Japan;Netherlands;Puerto Rico;Spain;United Kingdom;United States
   aTyr Pharma, Inc.
      2023   Phase 3   EUCTR2022-001012-26-FR   France;Germany;Italy;Japan;Netherlands;Puerto Rico;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2022-001012-26-NL   France;Germany;Italy;Japan;Netherlands;Puerto Rico;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004244-33-DE   Germany;United States
ATYR1923 1.0 MG/KG
   aTyr Pharma, Inc.
      2019   Phase 1/Phase 2   NCT03824392   United States
ATYR1923 3.0 MG/KG
   aTyr Pharma, Inc.
      2019   Phase 1/Phase 2   NCT03824392   United States
ATYR1923 5.0 MG/KG
   aTyr Pharma, Inc.
      2019   Phase 1/Phase 2   NCT03824392   United States
Autologous hematopoietic stem cell transplantation
   Northwestern University
      2003   Phase 1/Phase 2   NCT00282438   United States
Aviptadil
   Universitätsklinikum Freiburg, Leitender Ärztlicher Direktor
      2021   Phase 2   EUCTR2017-004219-37-DE   Germany
Azathioprine
   Assistance Publique Hôpitaux de Paris (APHP)
      2021   Phase 4   EUCTR2020-006022-32-FR   France
Azithromycin
   Vanderbilt University
      2014   Phase 2   NCT02024555   United States
      2010   Phase 1   NCT01169038   United States
Azithromycin 250MG capsule
   Hull University Teaching Hospitals NHS Trust
      2019   Phase 2   NCT04020380   United Kingdom
Azithromycin monohydrate
   Hull & East Yorkshire Hospitals NHS trust
      2019   Phase 2   EUCTR2019-000580-24-GB   United Kingdom
Bardoxolone methyl
   Reata, a wholly owned subsidiary of Biogen
      2014   Phase 2   NCT02036970   Germany;Spain;United Kingdom;United States
Baricitinib (LY3009104) 4 MG
   Stanford University
      2025   Phase 2   NCT06868381   United States
Blood sample
   University Hospital, Bordeaux
      2025   -   NCT06854848   France
   Vastra Gotaland Region
      2020   -   NCT04206163   Sweden
Bosentan
   Daniel Doberer
      2009   Phase 2   NCT00926627   Austria
   Medical University of Vienna, Department of Clinical Pharmacology
      2008   -   EUCTR2007-005117-18-AT   Austria
   University of Cincinnati
      2008   Phase 2/Phase 3   NCT00581607   United States
Bosentan monohydrate
   St Georges Hospital
      2007   Phase 4   EUCTR2006-005361-19-GB   United Kingdom
Bronchoscopy with bronchoalveolar lavage
   Kevin F. Gibson
      2014   -   NCT02134717   United States
C11-methionine
   Turku PET Centre
      2016   Phase 2   EUCTR2015-001815-11-FI   Finland
Calcium citrate with vitamin D2
   University of Texas Southwestern Medical Center
      2010   Phase 4   NCT03621553   United States
Canakinumab
   Novartis Pharma Services AG
      2016   Phase 2   EUCTR2016-001255-49-NL   Germany;Netherlands;United States
      2016   Phase 2   EUCTR2016-001255-49-DE   Germany;Netherlands;United States
      2015   -   EUCTR2013-005333-21-NL   Netherlands;United States
CC-100004
   University of Cincinnati
      2008   Phase 2/Phase 3   NCT00794274   United States
CC-220 0.3 MG daily
   Celgene
      2014   Phase 2   NCT02192489   -
CC-220 0.6MG daily
   Celgene
      2014   Phase 2   NCT02192489   -
Cellulose
   University of Maryland, Baltimore
      2025   Phase 2   NCT05910554   -
Cenplacel-L
   Celularity Incorporated
      2011   Phase 1   NCT01440192   United States
Ciclesonide
   Department of Respirology, Graduate School of Medicine, Chiba University, Chiba, Japan
      2014   -   JPRN-UMIN000013831   Japan
Clarithromycin
   National cerebral and cardiovascular center
      2017   -   JPRN-UMIN000025936   Japan
   Takase Hiroshi
      2017   Phase 1-2   JPRN-jRCTs031180301   -
CMK389
   Novartis Pharma AG
      2020   Phase 2   EUCTR2018-000381-11-PL   Czech Republic;Czechia;Denmark;Germany;Poland;United Kingdom;United States
      2020   Phase 2   EUCTR2018-000381-11-GB   Czech Republic;Denmark;Germany;Poland;United Kingdom;United States
      2020   Phase 2   EUCTR2018-000381-11-DK   Czech Republic;Czechia;Denmark;Germany;Poland;United Kingdom;United States
      2020   Phase 2   EUCTR2018-000381-11-DE   Czech Republic;Czechia;Denmark;Germany;Poland;United Kingdom;United States
      2020   Phase 2   EUCTR2018-000381-11-CZ   Czech Republic;Czechia;Denmark;Germany;Poland;United Kingdom;United States
   Novartis Pharmaceuticals
      2020   Phase 2   NCT04064242   Czechia;Denmark;Germany;Poland;United Kingdom;United States
Cnto 148
   Centocor BV
      2009   -   EUCTR2009-010714-30-NL   Belgium;Denmark;France;Germany;Italy;Netherlands;United Kingdom
      2009   Phase 2   EUCTR2009-010714-30-FR   Belgium;Denmark;France;Germany;Italy;Netherlands;United Kingdom
   Janssen Biologics B.V.
      2009   Phase 2   EUCTR2009-010714-30-GB   Belgium;Denmark;France;Germany;Italy;Netherlands;United Kingdom
      2009   -   EUCTR2009-010714-30-DK   Belgium;Denmark;France;Germany;Italy;Netherlands;Romania;United Kingdom;United States
      2009   -   EUCTR2009-010714-30-DE   Belgium;Denmark;France;Germany;Italy;Netherlands;United Kingdom
      2009   -   EUCTR2009-010714-30-BE   Belgium;Denmark;France;Germany;Italy;Netherlands;Norway;United Kingdom;United States
CNTO1275
   CENTOCOR
      2010   -   EUCTR2009-010714-30-IT   Belgium;Denmark;France;Germany;Italy;Netherlands;United Kingdom
   Centocor BV
      2009   -   EUCTR2009-010714-30-NL   Belgium;Denmark;France;Germany;Italy;Netherlands;United Kingdom
      2009   Phase 2   EUCTR2009-010714-30-FR   Belgium;Denmark;France;Germany;Italy;Netherlands;United Kingdom
   Janssen Biologics B.V.
      2009   Phase 2   EUCTR2009-010714-30-GB   Belgium;Denmark;France;Germany;Italy;Netherlands;United Kingdom
      2009   -   EUCTR2009-010714-30-DK   Belgium;Denmark;France;Germany;Italy;Netherlands;Romania;United Kingdom;United States
      2009   -   EUCTR2009-010714-30-DE   Belgium;Denmark;France;Germany;Italy;Netherlands;United Kingdom
      2009   -   EUCTR2009-010714-30-BE   Belgium;Denmark;France;Germany;Italy;Netherlands;Norway;United Kingdom;United States
CNTO148
   CENTOCOR
      2010   -   EUCTR2009-010714-30-IT   Belgium;Denmark;France;Germany;Italy;Netherlands;United Kingdom
Corticosteroid
   Oregon Health and Science University
      2019   Phase 1   NCT03793439   United States
   The First Affiliated Hospital, Guangzhou Medical University
      2012   -   ChiCTR-IOR-15005953   -
CU-64 dotatate
   Rigshospitalet, Denmark
      2016   -   NCT02812849   Denmark
Cyclophosphamide
   National Heart, Lung, and Blood Institute (NHLBI)
      1978   Phase 2   NCT00000596   -
D-methylphenidate
   University of Cincinnati
      2006   Phase 4   NCT00361387   United States
Dapsone
   National Heart, Lung, and Blood Institute (NHLBI)
      1978   Phase 2   NCT00000596   -
Deltacortene*10CPR 25MG
   UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA
      2008   -   EUCTR2008-001340-39-IT   Italy
Deucravacitinib
   Yale University
      2025   Phase 2   NCT06725264   United States
Dexamethasone
   St. Antonius Hospital
      2013   Phase 3   NCT01920919   Netherlands
Dexamethasone 0,5MG
      2013   -   EUCTR2013-000242-18-NL   Netherlands
Dotanoc
   St. Antonius Hospital
      2016   Phase 2   EUCTR2016-002160-14-NL   Netherlands
   Turku University Hospital
      2016   Phase 2/Phase 3   NCT02824419   Finland
Doxycycline
   National cerebral and cardiovascular center
      2017   -   JPRN-UMIN000025936   Japan
Efzofitimod
   ATYR PHARMA, INC.
      2023   Phase 3   EUCTR2022-001012-26-IT   France;Germany;Italy;Japan;Netherlands;Puerto Rico;Spain;United Kingdom;United States
   aTyr Pharma, Inc.
      2023   Phase 3   EUCTR2022-001012-26-FR   France;Germany;Italy;Japan;Netherlands;Puerto Rico;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2022-001012-26-NL   France;Germany;Italy;Japan;Netherlands;Puerto Rico;Spain;United Kingdom;United States
Efzofitimod 3 MG/KG
   Mimaki Yoji
      2023   Phase 3   JPRN-jRCT2011220021   Brazil;France;Germany;Italy;Japan;Netherlands;Puerto Rico;Spain;United Kingdom;United States of America
   aTyr Pharma, Inc.
      2022   Phase 3   NCT05415137   Brazil;France;Germany;Italy;Japan;Netherlands;Puerto Rico;Spain;United Kingdom;United States
Efzofitimod 5 MG/KG
   aTyr Pharma, Inc.
      2022   Phase 3   NCT05415137   Brazil;France;Germany;Italy;Japan;Netherlands;Puerto Rico;Spain;United Kingdom;United States
Ergocalciferol
   University of Texas Southwestern Medical Center
      2010   Phase 4   NCT03621553   United States
Ethambutol
   Vanderbilt University
      2014   Phase 2   NCT02024555   United States
      2010   Phase 1   NCT01169038   United States
Faecal microbiota transplantation
   Odense University Hospital
      2023   Phase 2   NCT04924270   Denmark
FDG
   Turku PET Centre
      2016   Phase 2   EUCTR2015-001815-11-FI   Finland
FDG-PET/CT with RB82 myocardial perfusion imaging
   Yale University
      2017   Early Phase 1   NCT03048097   United States
Fermented oyster extract
   Pusan National University Yangsan Hospital
      2019   -   NCT04109911   Korea, Republic of
Fluorine (18F) fludeoxyglucose
   Turku PET Centre
      2016   Phase 2   EUCTR2015-001815-11-FI   Finland
Fluorodeoxyglucose
   Yale University
      2017   Early Phase 1   NCT03048097   United States
Folic acid
   Murohara Toyoaki
      2016   Phase 3   JPRN-jRCTs041180111   -
   Toshiyuki Nagai
      2021   Phase 3   JPRN-jRCTs011210048   Canada;Japan;United Kingdom;United States
GA-68-DOTA-NOC
   St. Antonius Hospital
      2016   Phase 2   EUCTR2016-002160-14-NL   Netherlands
Gallium-68 dotatate
   Marcelo F. Di Carli, MD, FACC
      2015   -   NCT02546388   United States
   University of Pennsylvania
      2018   -   NCT03746847   United States
Gallium-68-DOTA-N-octreotide
   St. Antonius Hospital
      2016   Phase 2   EUCTR2016-002160-14-NL   Netherlands
Genetic analysis BY sanger and whole exome next generation sequencing
   Hospices Civils de Lyon
      2008   -   NCT02829853   France
Golimumab
   CENTOCOR
      2010   -   EUCTR2009-010714-30-IT   Belgium;Denmark;France;Germany;Italy;Netherlands;United Kingdom
   Centocor, Inc.
      2009   Phase 2   NCT00955279   Belgium;Denmark;France;Germany;Netherlands;Norway;Romania;Sweden;United Kingdom;United States
Golimumab liquid IN prefilled syringe
   Centocor BV
      2009   -   EUCTR2009-010714-30-NL   Belgium;Denmark;France;Germany;Italy;Netherlands;United Kingdom
      2009   Phase 2   EUCTR2009-010714-30-FR   Belgium;Denmark;France;Germany;Italy;Netherlands;United Kingdom
   Janssen Biologics B.V.
      2009   Phase 2   EUCTR2009-010714-30-GB   Belgium;Denmark;France;Germany;Italy;Netherlands;United Kingdom
      2009   -   EUCTR2009-010714-30-DK   Belgium;Denmark;France;Germany;Italy;Netherlands;Romania;United Kingdom;United States
      2009   -   EUCTR2009-010714-30-DE   Belgium;Denmark;France;Germany;Italy;Netherlands;United Kingdom
      2009   -   EUCTR2009-010714-30-BE   Belgium;Denmark;France;Germany;Italy;Netherlands;Norway;United Kingdom;United States
H.P. acthar GEL
   University of Maryland, Baltimore
      2016   Phase 4   NCT02298491   United States
Habitrol
   Ohio State University
      2015   Phase 1/Phase 2   NCT02265874   United States
Heparin
   Tokushima University Hospital
      2010   -   JPRN-UMIN000004267   Japan
Human anti TNF-alpha monoclonal antibody
   Centocor BV
      2009   -   EUCTR2009-010714-30-NL   Belgium;Denmark;France;Germany;Italy;Netherlands;United Kingdom
      2009   Phase 2   EUCTR2009-010714-30-FR   Belgium;Denmark;France;Germany;Italy;Netherlands;United Kingdom
   Janssen Biologics B.V.
      2009   Phase 2   EUCTR2009-010714-30-GB   Belgium;Denmark;France;Germany;Italy;Netherlands;United Kingdom
      2009   -   EUCTR2009-010714-30-DK   Belgium;Denmark;France;Germany;Italy;Netherlands;Romania;United Kingdom;United States
      2009   -   EUCTR2009-010714-30-DE   Belgium;Denmark;France;Germany;Italy;Netherlands;United Kingdom
      2009   -   EUCTR2009-010714-30-BE   Belgium;Denmark;France;Germany;Italy;Netherlands;Norway;United Kingdom;United States
Human ANTI-IL 12/23 monoclonal antibody
   Centocor BV
      2009   -   EUCTR2009-010714-30-NL   Belgium;Denmark;France;Germany;Italy;Netherlands;United Kingdom
      2009   Phase 2   EUCTR2009-010714-30-FR   Belgium;Denmark;France;Germany;Italy;Netherlands;United Kingdom
   Janssen Biologics B.V.
      2009   Phase 2   EUCTR2009-010714-30-GB   Belgium;Denmark;France;Germany;Italy;Netherlands;United Kingdom
      2009   -   EUCTR2009-010714-30-DK   Belgium;Denmark;France;Germany;Italy;Netherlands;Romania;United Kingdom;United States
      2009   -   EUCTR2009-010714-30-DE   Belgium;Denmark;France;Germany;Italy;Netherlands;United Kingdom
      2009   -   EUCTR2009-010714-30-BE   Belgium;Denmark;France;Germany;Italy;Netherlands;Norway;United Kingdom;United States
Humira
   Rigshospitalet
      2006   Phase 2   EUCTR2006-001816-56-DK   Denmark
   Wright State University
      2009   Phase 2   NCT00731757   United States
Hydroxychloroquine
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS
      2021   Phase 3   EUCTR2021-001834-20-FR   France
   Hospices Civils de Lyon
      2024   Phase 4   NCT05841758   France
   UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA
      2008   -   EUCTR2008-001340-39-IT   Italy
Hydroxychloroquine + LOW-dose prednisone
   Assistance Publique - Hôpitaux de Paris
      2022   Phase 3   NCT05247554   -
Hydroxychloroquine + prednisone
   University of Milano Bicocca
      2009   Phase 3   NCT02200146   Italy
Ilaris
   Novartis Pharma Services AG
      2016   Phase 2   EUCTR2016-001255-49-NL   Germany;Netherlands;United States
      2016   Phase 2   EUCTR2016-001255-49-DE   Germany;Netherlands;United States
      2015   -   EUCTR2013-005333-21-NL   Netherlands;United States
Iloprost
   University of Cincinnati
      2006   Phase 4   NCT00403650   United States
Imod.FC, H-FCV3-N4
   aTyr Pharma, Inc.
      2019   Phase 2   EUCTR2018-004244-33-DE   Germany;United States
Indium-111 pentreotide
   Marcelo F. Di Carli, MD, FACC
      2015   -   NCT02546388   United States
Infliximab
   Assistance Publique - Hôpitaux de Paris
      2019   Phase 3   NCT03704610   France
   Assistance Publique Hôpitaux de Paris (APHP)
      2021   Phase 4   EUCTR2020-006022-32-FR   France
   Centocor, Inc.
      2003   Phase 3   NCT00073437   Austria;Belgium;France;Germany;Italy;Netherlands;Sweden;Switzerland;United Kingdom;United States
Influenza vaccine
   Shahid Beheshti Medical University
      2008   -   NCT00828828   Iran, Islamic Republic of
Inhaled treprostinil
   University of Florida
      2020   Phase 2   NCT03814317   United States
KIN-1902
   Kinevant Sciences GmbH
      2022   Phase 2   EUCTR2021-004794-31-NL   Belgium;France;Germany;Netherlands;Türkiye;United Kingdom;United States
      2022   Phase 2   EUCTR2021-004794-31-FR   Belgium;France;Germany;Netherlands;Turkey;United Kingdom;United States
      2022   Phase 2   EUCTR2021-004794-31-DE   Belgium;France;Germany;Netherlands;Türkiye;United Kingdom;United States
      2022   Phase 2   EUCTR2021-004794-31-BE   Belgium;France;Germany;Netherlands;Türkiye;United Kingdom;United States
KRP-R120
   aTyr Pharma, Inc.
      2023   Phase 3   EUCTR2022-001012-26-FR   France;Germany;Italy;Japan;Netherlands;Puerto Rico;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2022-001012-26-NL   France;Germany;Italy;Japan;Netherlands;Puerto Rico;Spain;United Kingdom;United States
L-methionine
   Turku PET Centre
      2016   Phase 2   EUCTR2015-001815-11-FI   Finland
Laboratory testing
   Oregon Health and Science University
      2019   Phase 1   NCT03793439   United States
Levaquin
   Vanderbilt University
      2010   Phase 1   NCT01169038   United States
Levofloxacin
   Vanderbilt University
      2014   Phase 2   NCT02024555   United States
LOW dose prednisolone
   Postgraduate Institute of Medical Education and Research
      2017   Phase 4   NCT03265405   India
Medium dose prednisolone
   Postgraduate Institute of Medical Education and Research
      2017   Phase 4   NCT03265405   India
Metformin
   University of Maryland, Baltimore
      2025   Phase 2   NCT05910554   -
Methionine
   Turku University Hospital
      2016   Phase 2/Phase 3   NCT02824419   Finland
Methotrexate
   Assistance Publique - Hôpitaux de Paris
      2009   Phase 4   NCT00918554   France
   Assistance Publique Hôpitaux de Paris (APHP)
      2021   Phase 4   EUCTR2020-006022-32-FR   France
   Erasmus Medical Center
      2020   Phase 4   NCT04314193   Netherlands
   Erasmus Medisch Centrum Dept. of Pulmonology
      2020   Phase 4   EUCTR2019-004148-31-NL   Netherlands
   Izumi Chisato
      2023   -   JPRN-jRCTs051230077   -
   Ottawa Heart Institute Research Corporation
      2019   Phase 3   NCT03593759   Canada;Japan;United Kingdom;United States
   The Department of Cardiology, Nagoya University Graduate School of Medicine
      2016   -   JPRN-UMIN000022996   Japan
   Toshiyuki Nagai
      2021   Phase 3   JPRN-jRCTs011210048   Canada;Japan;United Kingdom;United States
Methylphenidate
   University of East Anglia
      2016   -   NCT02643732   United Kingdom
Methylphenidate 10MG tablets
   Norfolk and Norwich University Hospital
      2016   Phase 2   EUCTR2016-000342-60-GB   United Kingdom
Methylprednisolone
   Assistance Publique - Hôpitaux de Paris
      2012   -   NCT01652417   France
Minomycin
   Takase Hiroshi
      2017   Phase 1-2   JPRN-jRCTs031180301   -
MMF
   Shanghai Pulmonary Hospital
      2025   Phase 4   ChiCTR2500100359   China
MT203
   Kinevant Sciences GmbH
      2022   Phase 2   EUCTR2021-004794-31-NL   Belgium;France;Germany;Netherlands;Türkiye;United Kingdom;United States
      2022   Phase 2   EUCTR2021-004794-31-FR   Belgium;France;Germany;Netherlands;Turkey;United Kingdom;United States
      2022   Phase 2   EUCTR2021-004794-31-DE   Belgium;France;Germany;Netherlands;Türkiye;United Kingdom;United States
      2022   Phase 2   EUCTR2021-004794-31-BE   Belgium;France;Germany;Netherlands;Türkiye;United Kingdom;United States
MTX
   Murohara Toyoaki
      2016   Phase 3   JPRN-jRCTs041180111   -
Mycophenolate
   Medical University of South Carolina
      2003   Phase 3   NCT00262132   United States
   Shanghai Pulmonary Hospital
      2025   Phase 4   ChiCTR2500100359   China
N-acetyl-cysteine
   National Jewish Health
      2011   -   NCT01587001   United States
Namilumab
   Kinevant Sciences GmbH
      2022   Phase 2   NCT05314517   Belgium;France;Germany;Netherlands;Turkey;United Kingdom;United States
      2022   Phase 2   EUCTR2021-004794-31-NL   Belgium;France;Germany;Netherlands;Türkiye;United Kingdom;United States
      2022   Phase 2   EUCTR2021-004794-31-FR   Belgium;France;Germany;Netherlands;Turkey;United Kingdom;United States
      2022   Phase 2   EUCTR2021-004794-31-DE   Belgium;France;Germany;Netherlands;Türkiye;United Kingdom;United States
Nicotine patch
   Elliott Crouser MD
      2008   Early Phase 1   NCT00701207   United States
Nintedanib
   Post Graduate Institute of Medical Education and Research, Chandigarh
      2024   Phase 4   NCT06479603   India
Normal saline FOR injection
   Pfizer
      2013   Phase 2   NCT01732211   United States
OATD-01
   Molecure S.A.
      2024   Phase 2   NCT06205121   Denmark;France;Germany;Greece;Norway;United Kingdom;United States
Octreotide
   Erasmus Medical Center
      2014   -   EUCTR2013-005376-17-NL   Netherlands
Open label namilumab
   Kinevant Sciences GmbH
      2022   Phase 2   NCT05351554   United States
Orencia
   Universitätsklinikum Freiburg
      2017   Phase 2   EUCTR2016-003360-39-DE   Germany
PD 0360324
   Pfizer
      2013   Phase 2   NCT01732211   United States
Pentoxifylline
   National Heart, Lung, and Blood Institute (NHLBI)
      1999   Phase 2   NCT00001877   United States
Pirfenidone
   University of Cincinnati
      2017   Phase 4   NCT03260556   United States
Plaquenil
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS
      2021   Phase 3   EUCTR2021-001834-20-FR   France
Plaquenil*25CPR RIV 200MG
   UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA
      2008   -   EUCTR2008-001340-39-IT   Italy
Prednisolone
   Izumi Chisato
      2023   -   JPRN-jRCTs051230077   -
   National cerebral and cardiovascular center
      2017   -   JPRN-UMIN000025936   Japan
   Post Graduate Institute of Medical Education and Research, Chandigarh
      2024   Phase 4   NCT06654934   India
   The First Affiliated Hospital, Guangzhou Medical University
      2012   -   ChiCTR-IOR-15005953   -
   University of Edinburgh
      2017   -   NCT03705884   United Kingdom
Prednison
   Erasmus Medisch Centrum Dept. of Pulmonology
      2020   Phase 4   EUCTR2019-004148-31-NL   Netherlands
Prednisone
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS
      2021   Phase 3   EUCTR2021-001834-20-FR   France
   Erasmus Medical Center
      2020   Phase 4   NCT04314193   Netherlands
   Erasmus Medisch Centrum Dept. of Pulmonology
      2020   Phase 4   EUCTR2019-004148-31-NL   Netherlands
   Kinevant Sciences GmbH
      2022   Phase 2   NCT05351554   United States
   National Heart, Lung, and Blood Institute (NHLBI)
      1978   Phase 2   NCT00000596   -
   Ottawa Heart Institute Research Corporation
      2014   Phase 4   NCT01210677   Canada
   Toshiyuki Nagai
      2021   Phase 3   JPRN-jRCTs011210048   Canada;Japan;United Kingdom;United States
   UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA
      2008   -   EUCTR2008-001340-39-IT   Italy
Prednisone or prednisolone
   Celgene
      2017   -   NCT03324503   Netherlands;United Kingdom;United States
   Ottawa Heart Institute Research Corporation
      2019   Phase 3   NCT03593759   Canada;Japan;United Kingdom;United States
Quercetin
   Maastricht University Medical Center
      2006   -   NCT00402623   Netherlands
Rapamune
   Medical University of Vienna
      2019   Phase 2   EUCTR2017-004930-27-AT   Austria
Remicade
   St. Antonius Hospital
      2015   -   EUCTR2014-002224-26-NL   Netherlands
Repository corticotropin injection
   The Cleveland Clinic
      2019   Phase 4   NCT02920710   United States
Repository corticotropin injection -treatment extension
   The Cleveland Clinic
      2016   -   NCT02725177   United States
Rifampin
   Vanderbilt University
      2014   Phase 2   NCT02024555   United States
      2010   Phase 1   NCT01169038   United States
Rilonacept
   Mayo Clinic
      2025   Phase 2   NCT06660732   United States
Riociguat
   University of Cincinnati
      2015   Phase 4   NCT02625558   United States
Rituximab
   University of Cincinnati
      2009   Phase 2   NCT00855205   United States
RNA sequencing
   Oregon Health and Science University
      2019   Phase 1   NCT03793439   United States
Roflumilast
   University of Cincinnati
      2013   Phase 4   NCT01830959   United States
Rubidium
   Yale University
      2017   Early Phase 1   NCT03048097   United States
Rubidium PET
   Assistance Publique - Hôpitaux de Paris
      2012   -   NCT01648933   France
Sandostatin LAR
   Erasmus Medical Center
      2014   -   EUCTR2013-005376-17-NL   Netherlands
Sarilumab
   Stanford University
      2019   Phase 2   NCT04008069   United States
Schisandra chinensis extract
   Pusan National University Yangsan Hospital
      2017   -   NCT03402308   Korea, Republic of
Seasonal influenza vaccine available FOR THE 2012-2013 vaccine campaign
   Assistance Publique - Hôpitaux de Paris
      2012   Phase 3   NCT01687517   France
Selexipag
   ACTELION PHARMACEUTICALS LTD
      2019   Phase 2;Phase 3   EUCTR2018-004887-74-IT   Belgium;Brazil;Canada;Czechia;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
   Actelion
      2021   Phase 2   NCT03942211   Belgium;Brazil;Canada;Czechia;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
   Actelion Pharmaceuticals Ltd
      2020   Phase 2   EUCTR2018-004887-74-DE   Belgium;Brazil;Canada;Czechia;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
      2019   Phase 2;Phase 3   EUCTR2018-004887-74-PL   Argentina;Belgium;Brazil;Canada;China;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004887-74-NL   Belgium;Brazil;Canada;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
      2019   Phase 2;Phase 3   EUCTR2018-004887-74-HU   Argentina;Belgium;Brazil;Canada;China;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004887-74-GB   Belgium;Brazil;Canada;Czechia;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
      2019   Phase 2;Phase 3   EUCTR2018-004887-74-ES   Argentina;Belgium;Brazil;Canada;China;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
Semaglutide PEN injector
   University of Pennsylvania
      2024   Phase 1/Phase 2   NCT05746039   United States
Simultaneous combined 18F-FDG PET and cardiac MRI imaging
   University Health Network, Toronto
      2016   -   NCT03356756   Canada
Sirolimus ointment
   Medical University of Vienna
      2019   Phase 2   EUCTR2017-004930-27-AT   Austria
Skin biopsy
   Kevin F. Gibson
      2014   -   NCT02134717   United States
Sotagliflozin
   University of Pennsylvania
      2024   -   NCT06510894   United States
Spirometry
   Oregon Health and Science University
      2019   Phase 1   NCT03793439   United States
Stop ARM
   Assistance Publique - Hôpitaux de Paris
      2023   Phase 3   NCT05689879   France
Tadalafil
   University of North Carolina, Chapel Hill
      2011   Phase 2/Phase 3   NCT01324999   United States
Thalidomide
   Assistance Publique - Hôpitaux de Paris
      2005   Phase 3   NCT00305552   France
Tofacitinib 5 MG twice daily
   Yale University
      2019   Phase 1   NCT03910543   United States
Tofacitinib 5MG [xeljanz] 1 year OPEN-label extension
   Oregon Health and Science University
      2019   Phase 1   NCT03793439   United States
Tofacitinib 5MG oral tablet [xeljanz] 16 week trial
   Oregon Health and Science University
      2019   Phase 1   NCT03793439   United States
Tracleer
   Medical University of Vienna, Department of Clinical Pharmacology
      2008   -   EUCTR2007-005117-18-AT   Austria
   St Georges Hospital
      2007   Phase 4   EUCTR2006-005361-19-GB   United Kingdom
Tranilast
   The First Affiliated Hospital with Nanjing Medical University
      2018   Early Phase 1   NCT03528070   -
Uptravi
   ACTELION PHARMACEUTICALS LTD
      2019   Phase 2;Phase 3   EUCTR2018-004887-74-IT   Belgium;Brazil;Canada;Czechia;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
   Actelion Pharmaceuticals Ltd
      2020   Phase 2   EUCTR2018-004887-74-DE   Belgium;Brazil;Canada;Czechia;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
      2019   Phase 2;Phase 3   EUCTR2018-004887-74-PL   Argentina;Belgium;Brazil;Canada;China;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004887-74-NL   Belgium;Brazil;Canada;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
      2019   Phase 2;Phase 3   EUCTR2018-004887-74-HU   Argentina;Belgium;Brazil;Canada;China;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004887-74-GB   Belgium;Brazil;Canada;Czechia;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
      2019   Phase 2;Phase 3   EUCTR2018-004887-74-ES   Argentina;Belgium;Brazil;Canada;China;Czech Republic;Denmark;France;Germany;Hungary;India;Italy;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
Urine sample
   University Hospital, Bordeaux
      2025   -   NCT06854848   France
Ursodeoxycholic acid
   Ethan Weinberg
      2018   Phase 2   NCT03602976   United States
Ustekinumab
   CENTOCOR
      2010   -   EUCTR2009-010714-30-IT   Belgium;Denmark;France;Germany;Italy;Netherlands;United Kingdom
   Centocor, Inc.
      2009   Phase 2   NCT00955279   Belgium;Denmark;France;Germany;Netherlands;Norway;Romania;Sweden;United Kingdom;United States
Ustekinumab liquid IN prefilled syringe
   Centocor BV
      2009   -   EUCTR2009-010714-30-NL   Belgium;Denmark;France;Germany;Italy;Netherlands;United Kingdom
      2009   Phase 2   EUCTR2009-010714-30-FR   Belgium;Denmark;France;Germany;Italy;Netherlands;United Kingdom
   Janssen Biologics B.V.
      2009   Phase 2   EUCTR2009-010714-30-GB   Belgium;Denmark;France;Germany;Italy;Netherlands;United Kingdom
      2009   -   EUCTR2009-010714-30-DK   Belgium;Denmark;France;Germany;Italy;Netherlands;Romania;United Kingdom;United States
      2009   -   EUCTR2009-010714-30-DE   Belgium;Denmark;France;Germany;Italy;Netherlands;United Kingdom
      2009   -   EUCTR2009-010714-30-BE   Belgium;Denmark;France;Germany;Italy;Netherlands;Norway;United Kingdom;United States
Venipunctures
   Kevin F. Gibson
      2014   -   NCT02134717   United States
Xtmab-16
   Xentria, Inc.
      2024   Phase 2   NCT06169397   United Kingdom;United States
      2023   Phase 1/Phase 2   NCT05890729   Czechia;Denmark;Poland;Spain;United Kingdom;United States